|
|
News Breaks | | | | December 27, 2012 | | 17:22 EDT |  | OMER | Omeros down after trial does not meet all endpoints
"We are pleased with the outcome of this trial," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While not meeting all endpoints, the consistently positive results on pain reduction and the series of related inflammatory measures mark a clear path to approval of OMS103HP. The arthroscopy market is large and these data, together with an early 2013 NDA submission for our ophthalmic surgery product OMS302, set the stage for potentially two near-term market launches." | |
|
News For OMER From The Last 14 Days Check below for free stories on OMER the last two weeks. |
|
|
| June 13, 2013 | | 07:01 EDT | | OMER | Omeros obtains regulatory approval to initiate Phase 1 clinical trial for OMS721
Omeros announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 program. The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of OMS721 administered subcutaneously in healthy subjects. Omeros plans to follow this study with a clinical trial evaluating OMS721 in patients with atypical hemolytic uremic syndrome, a rare but life-threatening form of thrombotic microangiopathy. Enrollment in the initial clinical trial is scheduled to begin next month. | |
|
|
|
|
|
|
